Tag: Revive Therapeutics - Page 4 - Psychedelic Alpha

Read more about the article Revive Therapeutics Acquires Unique Psilocybin Assets

Revive Therapeutics Acquires Unique Psilocybin Assets

Post published:February 17, 2021
Post category:Press Release

Read more about the article Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

Post published:January 14, 2021
Post category:Press Release

Read more about the article Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

Post published:December 31, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

Post published:December 23, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program

Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program

Post published:December 21, 2020
Post category:Press Release

Read more about the article Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

Post published:December 2, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

Post published:November 18, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

Post published:November 11, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Post published:October 26, 2020
Post category:Press Release

Read more about the article Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

Post published:October 20, 2020
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.